Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Stay on top of the latest market trends
Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.
Sports news worthy of your time
Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.
Tech news worthy of your time
Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.
Get the inside stories
Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Want a daily digest of the top Denver news?
Get a daily digest of the most important stories affecting your hometown with Axios Denver
Want a daily digest of the top Des Moines news?
Get a daily digest of the most important stories affecting your hometown with Axios Des Moines
Want a daily digest of the top Twin Cities news?
Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities
Want a daily digest of the top Tampa Bay news?
Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay
Want a daily digest of the top Charlotte news?
Get a daily digest of the most important stories affecting your hometown with Axios Charlotte
Bottles of antiretroviral drug Truvada. Photo: Justin Sullivan/Getty Images
The Justice Department is reviewing the government patent for use of an HIV prevention drug, potentially signaling that it's considering action against the drugmaker that sells it, the Washington Post reports.
The bottom line: The drug, Truvada, is owned by Gilead, which sells it for between $1,600 and 2,000 a month.
Details: A retired Centers for Disease Control scientist told the Post that a Justice Department lawyer visited the CDC last month to talk to government scientists who discovered Truvada's preventative use.
- Gilead says the government's patent is invalid.
Why it matters: Truvada is key to the administration's goal of eradicating HIV by 2030, as it helps prevent new infections. But its price tag is creating patient access issues.
"We are in discussions with the government to determine the best ways to broaden access to Truvada for PrEP to vulnerable populations in the United States and support the federal plan to end the HIV epidemic."— Gilead's statement to the Post
The big picture: It's rare for the government to sue for drug patent infringement, although the Department of Health and Human Services has patented more than 2,500 products since 1976, WashPost reported last month.
- These discoveries were publicly financed, but the government often licenses them to private drug companies, which commercialize them.
Go deeper: Big Pharma's GOP firewall is weakening